

**Amendment #3 to RFP-NIH-NIAID-DMID-03-29**  
**"Production and Testing of Anthrax Recombinant Protective Antigen (rPA) Vaccine"**

---

**Amendment to Solicitation No.:** NIH-NIAID-DMID-03-29

**Amendment No.:** 3

**Issue Date:** June 17, 2003

**Effective Date:** June 17, 2003

**Proposal Due Date:** July 1, 2003, at 4:00 P.M. local time

**Issued By:** Elizabeth Osinski  
Contracting Officer  
NIH/NIAID  
Contract Management Branch  
6700 B Rockledge Drive  
Room 2230, MSC 7612  
Bethesda, Maryland 20892-7612

**Point of Contact:** Elizabeth Osinski, Contracting Officer  
Eo43m@nih.gov

**Name and Address of Offeror:** To All Potential Offerors

The above numbered solicitation is amended as set forth below. The hour and date specified for receipt of proposals **HAS NOT** been extended. Offerors must acknowledge receipt of this amendment. Failure to receive your acknowledgement of this amendment may result in the rejection of your offer. This amendment shall be acknowledged in the following manner:

- By acknowledging receipt of this amendment on each copy of the offer submitted.

**RFP No. NIH-NIAID-DMID-03-29 is amended as follows:**

**SECTION M – EVALUATION FACTORS FOR AWARD, item 4. MANDATORY QUALIFICATION CRITERIA, (MQC), criterion 4. a) is revised to read as follows:**

4.a) Offerors must provide a draft agreement signed by all parties involved outlining: (1) procedures to be used for obtaining patent coverage and licensing of the resulting vaccine, and (2) procedures to be followed for the resolution of potential legal issues that may arise. Initial proposals that do not include this agreement will be returned to the offeror without further review and will not be considered for award.

This draft agreement shall address how the Contractor plans to address intellectual property issues so that the vaccine can be manufactured by a commercial entity or a government contractor and made available. This draft agreement should identify existing intellectual property that will be needed to produce the final vaccine and include, for example, any reagents or technology that must be obtained from third parties to make the vaccine. The draft document may include information on the existence of agreements between the prime and subcontractors or third parties to license from each other.

**Note 16 in Amendment #2 is renumbered Note 15 and is revised to read as follows:**

**Note 15:**

Offerors are reminded that initial proposals must contain a draft agreement signed by all parties involved outlining: (1) procedures to be used for obtaining patent coverage and licensing of the resulting vaccine, and (2) procedures to be followed for the resolution of potential legal issues that may arise. Initial proposals that do not include this agreement will be returned to the offeror without further review and will not be considered for award. (Refer to Mandatory Criterion 4.a)